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Several genetic strategies for inhibiting neuro-
nal function in mice have been described, but
no system that directly suppresses membrane
excitability and is triggered by a systemically
administered drug, has been validated in awake
behaving animals. We expressed unilaterally in
mouse striatum a modified heteromeric iver-
mectin (IVM)-gated chloride channel from C.
elegans (GluClab), systemically administered
IVM, and then assessed amphetamine-induced
rotational behavior. Rotation was observed as
early as 4 hr after a single intraperitoneal IVM in-
jection (10mg/kg), reachedmaximal levels by12
hr, andwas almost fully reversedby4days.Mul-
tiple cycles of silencing and recovery could be
performed in a single animal. In striatal slice
preparations fromGluClab-expressing animals,
IVM rapidly suppressed spiking. The two-sub-
unit GluCl/IVM system permits ‘‘intersectional’’
strategies designed to increase the cellular
specificity of silencing in transgenic animals.
INTRODUCTION
Genetic tools provide a powerful approach to establishing
causal relationships between the activity of specific neu-
ronal circuits and behavior (reviewed in Callaway [2005],
Deisseroth et al. [2006], Schafer [2005]). Recently, various
methods have been developed to reversibly silence neu-
ronal activity with genetically encoded effector molecules
in mammalian systems. Several (but not all) of these sys-
tems have also been employed in Drosophila (Thum
et al., 2006). Two fundamentally different approaches
have been undertaken: the first targets neurotransmitter
release and the second neuronal excitability. Within these
two categories, reversibility has been achieved using ei-ther transcriptional control or protein activation/inactiva-
tion. While significant progress has been made, each of
these methods has different limitations, and many have
not been tested for their ability to perturb behavior in freely
moving animals.
Two methods for inhibiting neurotransmitter release
have been used in mice. Tetanus toxin light chain (TNT)
was used to cleave VAMP2/Synaptobrevin, a synaptic
vesicle protein (Yamamoto et al., 2003; Yu et al., 2004).
Regulation is achieved by inducible transcription, and re-
covery occurs when the cell resynthesizes VAMP2. While
this system can influence behavior (Yamamoto et al.,
2003), the transcriptional induction has a relatively slow
onset of 14 days. More recently, small molecule-induced
crosslinking of genetically modified forms of VAMP2
(‘‘MIST’’) was shown to inhibit neurotransmission in vitro
and also to influence behavior in vivo, when expressed
in cerebellar Purkinje cells (Karpova et al., 2005). This is
a potentially powerful method; however, the crosslinking
agent was delivered intracerebroventricularly (ICV) and
has not yet been tested using systemic administration.
More importantly, because this approach does not di-
rectly suppress neuronal excitability, the postsynaptic tar-
gets of themanipulated neuronsmust already be known in
order to validate silencing electrophysiologically (Karpova
et al., 2005; Yu et al., 2004).
Several genetically encoded suppressors of membrane
excitability have been developed. These methods permit
validationof silencing in the targetedneurons,withoutprior
knowledge of their postsynaptic targets. The strongly rec-
tifying potassium channel Kir2.1 silences neurons (Johns
et al., 1999; Nitabach et al., 2002; Yu et al., 2004) and, un-
like weakly rectifying potassium channels (Nadeau et al.,
2000), does not kill cells due to potassium leak. Because
these channels are constitutively active, however, revers-
ibility must be achieved through transcriptional control.
Similarly, electrical silencinghasbeenachievedbyexpres-
sion of membrane-tethered toxins that bind sodium
channels or nicotinic receptors (Ibanez-Tallon et al., 2004),
but reversibility also requires inducible transcriptionalNeuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc. 35
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protein-coupled receptor (GPCR) for the Drosophila neu-
ropeptide allatostatin (Lechner et al., 2002). This elegant
method rapidly and reversibly silences neuronal spiking
activity in vivo (Gosgnach et al., 2006; Tan et al., 2006).
However, because the ligand is a neuropeptide, it does
not cross the blood-brain barrier (BBB) and therefore must
be delivered ICV, an inconvenient method when many an-
imals are required for behavioral experiments. None of
these methods, moreover, has been validated in awake
behavingmice. To date, therefore, no study has described
a method that reversibly suppresses neuronal excitability,
is gated by a ligand that crosses the BBB, and that demon-
strably affects behavior in freely moving animals.
We previously described a method for regulated inhibi-
tion of neuronal excitability, employing coexpression of
two subunits (a and b) that comprise a C. elegans glu-
tamate- and ivermectin (IVM)-gated chloride channel
(GluClab; Slimko et al., 2002). This heteromeric channel
prevents action potential firing by hyperpolarizing the
membrane in a ligand-dependent manner. Coexpression
of the two subunits in cultures of dissociated hippocampal
neurons, followed by IVM application, effectively sup-
pressed spiking (Slimko et al., 2002). Subsequently, we
codon-optimized GluClab for mammalian expression, re-
duced sensitivity to endogenous glutamate by site-di-
rected mutagenesis, and incorporated fluorescent moie-
ties to facilitate detection of expression (Li et al., 2002;
Slimko and Lester, 2003).
These in vitro studies left open the question of whether
the GluCl/IVM system is efficacious in vivo. Ivermectin at
veterinary doses has little or no effect on mouse behavior
(Davis et al., 1999), but it remained unclear whether (1)
stable expression of GluClab could be achieved in vivo
without neurotoxicity, (2) significant IVM-independent
baseline silencing would occur due to local glutamate
release, (3) IVM could cross the BBB at levels sufficiently
high to activate GluClab without organismal toxicity, (4)
GluCl/IVM activation would be reversible in vivo, and (5)
GluCl/IVM-mediated neuronal silencing could be used to
manipulate behavior in awake, freely moving animals.
Here, we present evidence that the GluClab channel
can be activated by systemic administration of IVM in
vivo, that GluCl/IVM-dependent silencing of striatal neu-
rons can influence behavior without measurable neuronal
or organismal toxicity, and that repeated cycles of silenc-
ing and recovery can be obtained within individual
animals. This two-subunit system is well suited to ‘‘inter-
sectional’’ strategies designed to increase the cellular
specificity of silencing in transgenic animals.
RESULTS
Expression of GluCl Channel Subunits
in the Striatum
To test whether the GluCl/IVM system can be used for
in vivo silencing, we expressed independently each of the
codon-optimized, FP-tagged subunits, called optGluCla-36 Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc.CFP and optGluClbY182F-YFP (Li et al., 2002; Slimko
and Lester, 2003), using an adenoassociated virus (AAV)
vector (Figure 1A). Transcription was driven by a cytomeg-
alovirus (CMV) early promoter, and a woodchuck hepatitis
posttranscriptional regulatory element (WPRE) was in-
serted for additional enhancement of expression (Fig-
ure 1A). Both constructs were commercially packaged
and serotyped with the AAV2 capsid protein (Virapur,
Inc.), yielding titers of 1012 particles per ml. We refer to
the viruses encoding the a and b subunit as AAV2-a and
AAV2-b, respectively (Figure 1A).
We injected a mixture of both viruses into several brain
regions and found that the striatum allows for good virus
spread (Figure 1B). Striatal injection of 2 ml of the virus sus-
pension (approximately 23 109 particles) yielded infected
volumes of 0.5 to 1.6 mm3. Immunolabeling with anti-GFP
antibodies indicated that, as expected, GluClab is local-
ized to membranes and is visible in neuronal projections
(Figure 1C). Colabeling with NeuN, a neuronal nuclear
marker, confirmed that nearly all infected cells are neurons
(Figure 1C). Cell counts using confocal images of 20 mm
sections indicated that, within the infected region, close
to 80% of NeuN+ cells were infected (79.6% ± 1.3%,
mean ± SEM, n = 10 sections).
IVM-dependent silencing occurs only if both a and b
subunits of the heteromeric channel are expressed in the
same cell. To assess the extent of coexpression, we visu-
alizednativeCFPandYFPfluorescenceusingconfocalmi-
croscopy. The majority of infected cells in the striatum
coexpressedboth subunits (Figures 1Hand1I).Control ex-
periments using single-subunit infections confirmed the
absence of artifactual bleed-through fluorescence (Fig-
ures 1D–1G). While 50% of cells expressed both chan-
nels at comparable levels (Figures 1H and 1I, white ar-
rows), 50% expressed more strongly one or the other
subunit (Figures 1H and 1I, orange and red arrows). Never-
theless, all cells that showeda strong signal for one subunit
also showed detectable expression of the other subunit.
IVM-Dependent Silencing by GluCl/IVM In Vivo
To assess whether neuronal silencing by GluCl/IVM can
produce behavioral phenotypes in vivo, we sought a rela-
tively simple system with a robust and reproducible be-
havioral response that is sensitive to perturbation of neu-
ronal activity. The striatum plays an important role in
relaying dopaminergic signaling from the substantia nigra
to motor and sensory areas (Graybiel, 2005). Unilateral
disruption of nigrostriatal signaling has been extensively
employed in animal models of movement disorders,
such as Parkinson’s disease (Willis and Kennedy, 2004).
Because such manipulations produce only subtle effects
on spontaneous locomotor activity in rodents, a widely
used assay employs systemic administration of amphet-
amine (AMP) to enhance locomotion (Ungerstedt, 1971).
In animals bearing unilateral damage to the striatum or
the substantia nigra, AMP produces a relative enhance-
ment of dopaminergic transmission in the contralateral
(control) striatum, causing rotations toward the lesioned
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GluCl/IVM-Dependent Silencing of Striatal NeuronsFigure 1. AAV2-Mediated Expression of GluCl Receptor Subunits in the Striatum
(A) Schematic representation of the viral constructs. CMV, cytomegalovirus promoter. optGluCla-CFP and optGluClbY182F-YFP, mutated (b182F),
codon-optimized GluCl-ion channel subunits fused to CFP and YFP, respectively (Slimko and Lester, 2003). WPRE, Woodchuck hepatitis posttran-
scriptional regulatory element. liTR and riTR, left and right inverted terminal repeat. pA, human growth hormone poly A-addition signal.
(B) Anti-GFP staining (red, dashed white line) reveals the extent of virus infection in the right striatum. Black counterstain is NeuN.
(C) Double staining for GFP (green) and NeuN (red) shows neuronal restriction of viral expression, as well as presence of GluClab in processes.
(D–I) Native fluorescence of CFP- and YFP-tagged GluCl channel subunits.
(D and E) AAV2-optGluCla-CFP-infected striatum.
(F and G) AAV2-optGluClb-YFP-infected striatum.
(H and I) Striatum coinfected with AAV2-a- and AAV2-b-expressing viruses. White arrows indicate cells coexpressing high levels of both the a and
b subunits, while orange and red arrows indicate cells preferentially expressing a or b, respectively.Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc. 37side, i.e., ipsilaterally (Schwarcz et al., 1979; Ungerstedt
and Arbuthnott, 1970).
We used a variation of this assay in order to test for be-
havioral effects of GluCl/IVM-mediated neuronal silencing
(see Figure 2A). Two microliters of virus suspension (23
109 particles) was injected into one side of the striatum
at the level of bregma. The suspension contained either
AAV2-a or AAV2-b alone or a 1:1 mixture of both viruses
(AVV2-a + AAV2-b). Between 14 and 30 days after virus in-
jection, animals were injected intraperitoneally (i.p.) with
IVM (10 mg/kg). In preliminary studies, control mice in-
jected with this dosage of IVM showed no obvious impair-
ment of spontaneous locomotor activity in an open field
test or performance deficits in other locomotor-depen-
dent behavioral tests, such as the rotarod assay (see
Figure S1 in the Supplemental Data available with this
article online).
To assess rotational behavior, mice were given a single
intraperitoneal (i.p.) injection of AMP (5 mg/kg), and
placed into a square open field box (553 55 cm). Locomo-
tor trajectories (see examples in Figures 2F–2I) were re-
corded on videotape and analyzed using Ethovision 3.0software (Noldus, Inc.). The number of full 360 locomotor
circles, performed without any change in direction, was
counted during a 30 min period, beginning 10 min after
AMP injection (Figure 2A). Ipsilateral and contralateral ro-
tations (relative to the side injected with virus) were scored
as positive and negative, respectively. Because the ani-
mals were allowed to move freely during the test, we nor-
malized for the total distance traveled during the 30 min
scoring period; the parameter measured was thus the
net number of rotations (ipsilateral plus contralateral) per
10 min. Wider circles, such as those exhibited by control
mice when moving around the chamber perimeter, thus
yield a lower score than smaller circles.
Inmice injected with themixed virus suspension encod-
ing both subunits of GluCl and given IVM, administration of
AMP 12 hr later (Figure 2A) promoted strong unilateral ro-
tation activity, in the direction ipsilateral to the viral injec-
tion side (Figures 2B and 2I; Movie S1). The median rota-
tion score for (AAV2-a + AAV2-b)-injected animals was
significantly higher than in animals injected with the a virus
alone, the b virus alone, or no virus (sham injection;
ANOVA followed by post hoc Kolmogorov-Smirnov test;
Neuron
GluCl/IVM-Dependent Silencing of Striatal NeuronsFigure 2. Amphetamine-Induced Rotation Test for Silencing of Striatal Neurons
(A) Schematic of experimental design. Red patch in striatum (light blue) indicates extent of virus infection. The contralateral side of each coronal sec-
tion is Nissl stained (coronal diagrams from the Allen Brain Atlas, http://www.brain-map.org). IVM, ivermectin; AMP, amphetamine.
(B) Box plot illustrating distribution of rotation scores (see Experimental Procedures) for sham, AAV2-a-, AAV2-b-, and (AAV2-a + AAV2-b)-injected
animals. *Distributions for sham and (AAV2-a +AAV2-b) are significantly different (ANOVA for rotation scores AAV2-a and AAV2-b as factors; p < 105;
post hoc Kolmogorov-Smirnov (K-S) test; Z = 3.17, p = 0.0003).
(C) Histogram of rotation scores for animals injected with (AAV2-a + AAV2-b).
(D) Mean rotation scores for control (sham-, AAV2-a-, AAV2-b-injected animals pooled) and weak and strong rotators among (AAV2-a + AAV2-b)-
injected animals. **p < 0.001.
(E) Infection volume in the striatum of three (AAV2-a + AAV2-b)-injected animals showing a weak rotation phenotype versus three animals showing
a strong rotation phenotype. **p < 0.005. p values for (D) and (E) were determined using a two-tailed, unpaired t test assuming unequal variance. Error
bars represent ±SEM.
(F–I) Representative traces of 30 min AMP-induced rotation tests (Movie S1).p < 0.001; Figures 2B and 2G). There was no significant
difference (p > 0.3) between the results for any of these
three control groups (Figure 2B). Animals injected with
(AAV2-a + AAV2-b) showed no AMP-induced rotations in
the absence of IVM (Figure 2H). Thus, AMP-induced rota-
tions require the expression of bothGluCl subunits, aswell
as administration of IVM. Importantly, the fact that AMP-
sensitivity was achieved by i.p. injection of IVM indicates
that the ligand can cross the BBB at levels sufficient to
activate GluClab.
In preliminary time-course and dose-response experi-
ments, we found that each group of (AAV2-a + AAV2-b)-
injected mice contained some animals that appeared
unresponsive to IVM. To distinguish whether this variation
reflected the particular IVM dose or was time-point tested,
or rather a general lack of IVM responsiveness, all animals
from these experiments were retested at the end of the ex-
periment using a uniform IVM dose. IVM at 10 mg/kg was38 Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc.administered 16 days after the original injection (when the
initial response had decayed to baseline [Table 1]), and
AMP-induced rotation tested in all animals 12 hr later.
The resulting scores (n = 56 animals) were plotted as a his-
togram (Figure 2C). The data clearly exhibited a bimodal
distribution. One group of animals exhibited a weak
but significant rotation phenotype (Figures 2C and 2D,
‘‘weak’’; average = 2.3 ± 0.4 circles/10 min, n = 22) when
compared with the control groups (Figure 2D; pooled
average = 0.5 ± 0.2, n = 15, p < 0.001), while the second
group exhibited a strong rotation phenotype (Figures 2C
and 2D, ‘‘strong’’; average = 60.4 ± 1.7, n = 34). Similar
results were obtained comparing the total number of rota-
tions during the 30 min period (ipsilateral circles > 0, con-
tralateral circles < 0): control mice showed an average of
0.5 ± 4.6 circles (n = 15); animals with a weak phenotype,
22.9 ± 5.6 circles (n = 22); and animals with a strong phe-
notype, 251.2 ± 21.1 circles (n = 34).
Neuron
GluCl/IVM-Dependent Silencing of Striatal NeuronsTable 1. Kinetics of Onset and Decay of IVM Effect on Behavior
6 hr 12 hr 24 hr 2 days 3 days 4 days 5 days 14 days
IVM 5 mg/kg 2.7 ± 1.6 28.0 ± 7.8 44.7 ± 17.5 42.6 ± 15.7 20.2 ± 10.4 4.9 ± 3.0 5.0 ± 1.9 1.0 ± 0.5
IVM 10 mg/kg 23.2 ± 2.1 63.0 ± 13.6 47.2 ± 9.6 39.9 ± 11.3 50.5 ± 10.8 6.1 ± 1.5 4.6 ± 1.5 3.7 ± 1.8
p value 0.0004a 0.29 0.93 0.91 0.12 0.79 0.91 0.34
The upper two rows show rotation scores at the indicated time points after 5 mg/kg and 10 mg/kg IVM injection. The data for
5 mg/kg IVM are plotted in Figure 4D. The third row shows p values unpaired t tests of statistical significance between 5 mg/kg
and 10 mg/kg IVM injections.
a Significant after Bonferroni correction.To determine whether there was a correlation between
the strength of the rotation phenotype and the level of
striatal GluClab expression, three animals were chosen
randomly from each behavioral group (weak and strong)
and the volume of the virally infected region in their brains
determined by immunostaining for GFP and quantified us-
ing Stereo Investigator software (Microbrightfield, Inc.).
There was a significant difference between the weak and
strong groups in the volume of striatum expressing Glu-
Clab (Figure 2E; 0.5 ± 0.1 mm3 versus 1.7 ± 0.1 mm3,
respectively, p < 0.005). These data suggest that the non-
responsive animals have a lower extent of infection by
(AAV2-a + AAV2-b), which is below a threshold necessary
to elicit a strong behavioral phenotype.
IVM Inhibits Firing of Striatal Neurons in Slices
Derived from GluClab-Expressing Animals
To determine whether the AMP-induced, GluCl/IVM-de-
pendent rotation phenotype is associated with silencing
of neurons in the striatum, we measured firing by whole-
cell patch clamp recording, in striatal slices taken from an-
imals stereotaxically injected with an (AVV2-a + AAV2-b)
virus suspension. Recordings were performed within an
area of 750 mm around the presumptive injection site
(2.2 mm lateral, 2.5 mm to 4 mm ventral to bregma). Sig-
nals were obtained from two types of neurons: medium
spiny neurons (MSN, n = 12) and interneurons (IN, n = 20),
which were distinguished by their differences in resting
membrane potential (MSNs, 76 ± 3 mV; INs, 50 ± 2 mV;
Jiang and North, 1991; Wilson, 1998). The effect of bath-
applied IVM was determined on spontaneous action
potential firing (in the case of INs) or on firing evoked by in-
jection of depolarizing current (20–180 pA) in the case of
MSNs, whose baseline firing frequency was otherwise too
low for systematic studies on IVM effects. When 20 nM
IVM was applied to the slices from (AAV2-a + AAV2-b) in-
jected animals, we observed three types of responses
(Figures 3A–3C): (1) full inhibition of firing after 7min of per-
fusion with IVM (Figure 3A, 95% ± 2% inhibition of firing
rate, n = 12); (2) partial inhibition after 15 min of perfusion
with IVM (Figure 3B, 56% ± 5% inhibition, n = 6); (3) no in-
hibition (Figure 3C, n = 14). None of the neurons recorded
in control slices from sham-injected animals showed any
inhibition of firing after 15 min of IVM perfusion (data not
shown, n = 6). There was no statistical difference in the
proportion of MSNs and INs inhibited: 67% of MSNshowed inhibition (8/12; five strong, three weak) and
50% of IN were inhibited (10/20, five strong, five weak).
Previous studies characterizing GluClab expressed in
dissociated cultures of hippocampal neurons indicated
that inhibition of neuronal activity is accompanied by an in-
crease in membrane conductance and by hyperpolariza-
tion of the membrane potential (Slimko et al., 2002, Li
et al., 2002, Slimko and Lester, 2003), consistent with an
IVM-gated chloride conductance. Similarly, in striatal sli-
ces obtained from (AAV2-a + AAV2-b)-infected mice, we
observed a significant negative correlation (r = 0.62,
p < 0.01) between the rate of spike firing after IVM perfu-
sion, relative to baseline (‘‘% pre-IVM’’), and membrane
conductance (Gmemb; Figure 3D, left panel). A significant
increase in average Gmemb was observed in neurons
with full inhibition of firing (n = 5, p < 0.01) and partial
inhibition of firing (n = 4, p < 0.05; Figure 3D, right panel).
No change in Gmemb was observed in noninhibited neu-
rons. Spike firing after IVM perfusion (relative to baseline)
was also negatively correlated with membrane hyper-
polarization (Figure 3E, left panel; r = 0.81, n = 16, p <
0.0001). Both fully inhibited and partially inhibited neurons
showed a significant IVM-dependent hyperpolarization
(p < 0.01), while neurons showing no inhibition of firing,
showed no hyperpolarization (p > 0.1; Figure 3E, right
panel).
The expression of GluCla and b in virus-infected cells
varies among individual neurons within the injected area.
We sought to determine whether this variation in GluClab
levels correlates with the variation in the inhibition of spik-
ing by IVM. Prospective identification of GluClab-express-
ing neurons in striatal slices was challenging because of
the high levels of autofluorescence and expression of Glu-
Clab in processes, rather than somata. Thus, we recorded
from randomly selected cells in the infected area (one cell
per slice) and filled the cell with a far red fluorescent dye
(Alexa 647-dextran). After fixation of each 250 mm slice
and resectioning at 30 mm, we were able to unequivocally
identify six filled cells (Figure 3F). Quantitative spectral
analysis of each identified cell showed a negative correla-
tion between CFP and YFP fluorescence intensity and fir-
ing rate after IVM perfusion, relative to baseline (‘‘% pre-
IVM,’’ Figures 3G and 3H). Fully inhibited cells expressed
CFP and YFP at levels near the median of the population
and 15-fold lower than that of the most highly expressing
cells (Figure S2).Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc. 39
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(A–C) Traces and firing rates, showing the effect of IVM application on firing of neurons in slices from (AAV2-a + AAV2-b)-infected animals. Results are
pooled for neurons showing full (A), partial (B), and no (C) inhibition. (a, b, and c) indicate sample spike trains before (a) and after (b and c) IVM
perfusion.
(D) Left panel, the firing rate after IVM application, relative to baseline (‘‘% pre-IVM’’) is negatively correlated with an increase in membrane conduc-
tance (Gmemb) (r = 0.62, p < 0.01). Right panel, a significant increase in average Gmemb, relative to that pre-IVM, is observed in neurons with full
(**p < 0.01) and partial inhibition of firing (*p < 0.05), but not in neurons showing no inhibition.
(E) Left panel, the firing rate after IVM application, relative to baseline, is negatively correlated with hyperpolarization (r =0.81, p < 0.01). Right panel,
a significant increase in mean hyperpolarization is observed following IVM perfusion, in neurons with full and partial inhibition of firing, but not in neu-
rons showing no inhibition. **p < 0.01. p values for (D) and (E) were determined by a t test, assuming unequal variance. Error bars represent ±SEM.
(F) Integrated Z stacks of confocal images from a noninhibited neuron (left column) and a fully inhibited neuron (right column).
(G) CFP fluorescence intensity is negatively correlated with firing rate after IVM perfusion, relative to baseline (‘‘% pre-IVM;’’ r = 0.91, p < 0.005).
(H) YFP fluorescence is negatively correlated with firing rate after IVM, relative to baseline (r =0.91, p < 0.005). CFP and YFP fluorescence intensity in
each cell is normalized to the median intensity for 11 GluClab-expressing cells (see Figure S2).40 Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc.
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the behavioral phenotype produced by IVM in vivo and the
two types of firing inhibition (full and partial) observed in
slice recordings. Recordings from striatal neurons were
performed in slices from 13 (AAV2-a + AAV2-b)-injected
animals, 8 of which showed a strong rotation phenotype
(cf. Figure 2C), and 5 of which showed a weak phenotype,
as well as from three sham-injected animals, by a person
blind to the behavioral phenotype. There was a clear cor-
relation between the percentage of neurons showing full,
partial, or no inhibition, and the strength of the behavioral
phenotype (Figure 3I): slices from animals showing
a strong rotation phenotype exhibited the greatest propor-
tion of inhibited (full + partial) neurons (70%), and a high
percentage of such neuronswere fully inhibited (71%). In
addition, the median firing rate after IVM perfusion was
significantly lower in animals showing a strong rotation
phenotype than in sham-injected animals or animals with
a weak rotation phenotype (Figure 3J). Thus, the strength
of the rotation phenotype is correlated with the percent-
age of neurons inhibited by IVM, as well as with the
strength of inhibition. Taken together, the data indicate
that mice exhibiting a strong behavioral phenotype (Fig-
ure 2C) show both a greater extent of infection by AAV2-
GluClab (Figure 2E) and a greater extent of IVM-depen-
dent spike suppression in vitro.
IVM Dosage Sensitivity of GluClab-Dependent
Silencing In Vivo
We next investigated the minimum dose of IVM necessary
to elicit a rotation phenotype, using the experimental de-
sign shown in Figure 4A. Two weeks after viral infection,
GluClab-expressing animals were injected with AMP to
confirm the lack of significant rotation in the absence of
IVM (Figure 4A, ‘‘AMP’’; Figure 4B, ‘‘pretest’’). GluClab-
expressing mice were then injected 1 day later with a
single dose of IVM (Figure 4A, ‘‘IVM’’), using one of five dif-
ferent concentrations between 0 and 10 mg/kg (n = 4–5
animals per dose) and tested 12 hr later for AMP induced
rotation (Figure 4A, ‘‘AMP’’). ANOVA showed a significant
interaction between pretest versus posttest and IVM con-
centration (p < 106). Thus, we performed post hoc t tests
between pretest and posttest for the individual IVM con-
centrations. There was no significant effect, relative to
pretest, of IVM at doses %2.5 mg/kg (p > 0.05), while a
significant increase in rotation was observed at 5 mg/kg
IVM (p < 0.01, n = 5) and at 10 mg/kg (p < 0.005, n = 4;
Figure 4B). Although there was a trend toward a higher
mean rotation score at 10 mg/kg IVM compared to
5 mg/kg (Figure 4B), this difference was not statisticallysignificant (p > 0.2). To ensure that animals with similar
sensitivities to IVM were compared in the dose-response
experiment, 16 days following the AMP test (when the
IVM effect has decayed; see Figure 4D), all mice were
reinjected with 10 mg/kg IVM and tested after 12 hr for
AMP-induced rotation. Only data from animals exhibiting
a ‘‘strong’’ phenotype in this retest (Figure 2C; >10 ipsilat-
eral circles per 10min) were included in the dose response
study (10 of 31 animals were excluded by this criterion).
There was no statistically significant difference in rotation
score between animals not excluded by this retest (p >
0.1, data not shown).
Kinetics of Onset and Decay of IVM Effect
on Behavior
We next investigated the kinetics of the onset and decay
of IVM-dependent, AMP-induced rotation. Eight indepen-
dent groups of mice were injected with AAV2-a+ AAV2-
b (n = 3–6 animals/group). Two weeks after virus injection,
mice were pretested with AMP in order to establish base-
line behavior (Figure 4C, ‘‘AMP/pretest’’). One day later, all
mice received 5mg/kg IVM (Figure 4C, ‘‘IVM’’). At different
time points after the IVM injection, each group of mice was
injected with AMP and scored for rotational behavior
(Figure 4C, ‘‘scoring’’). At this dose of IVM, the earliest
time at which a statistically significant AMP-induced
rotation was observed was at 12 hr post-IVM injection
(p < 0.02; Figure 4D). A maximal effect was achieved by
24 hr and persisted for 2 days. The AMP-induced rotation
began to decline on day 3 (Figure 4D). The rotation scores
at 4 and 5 days post-IVM injection were not significantly
different from pretest controls, although a few animals
showed detectable circling. By 14 days after the IVM
injection, none of the animals showed a detectable AMP-
induced rotation. To ensure that all animals used in the
time-course experiment were capable of similar re-
sponses when tested with AMP at the same time interval
after IVM injection, at day 16 all animals were reinjected
with 10 mg/kg IVM and then tested 12 hr later for AMP-
induced rotation. Only data from animals scoring at least
10 circles/10 min were included in the analysis (34 out of
56 animals). There was no statistical difference between
the mean rotation scores for any groups not excluded by
this retest (p > 0.05, data not shown).
We also performed a similar time-course experiment
with animals receiving 10mg/kg IVM. In this case, a signif-
icant AMP-induced rotation response was observed as
early as 6 hr post-IVM, with maximal levels achieved by
12 hr and maintained to day 3 (Table 1). The rate of onset
for IVM at 10 mg/kg was significantly higher than that(I) Distribution of neurons showing different levels of IVM-dependent inhibition in slices from sham-injected animals or from (AAV2-a + AAV2-b)-in-
jected animals exhibiting weak or strong rotation responses to AMP. Light gray, percentage of neurons showing no response. Dark gray, percentage
of neurons showing partial inhibition. Black, percentage of neurons showing full inhibition.
(J) Box plots illustrating the reduction in firing rate from neurons of sham-injected animals versus (AAV2-a + AAV2-b)-injected animals showing
a strong or weak rotation phenotype, respectively. Horizontal line, median; lower box, 25th–50th percentile; upper box, 50th–75th percentile; lower
whisker, 10th–25th percentile; upper whisker, 75th–90th percentile. (a) Firing rates in slices from animals exhibiting a strong rotation phenotype are
significantly different from those in slices from sham-injected animals (Kruskal-Wallis Test, p = 0.03 [c2 = 7.03, df = 2]; post hoc K-S test, Z = 1.85,
p = 0.032), and animals with a weak rotation phenotype (K-S test, Z = 2.08, p = 0.019), which are not significantly different from each other (b).Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc. 41
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Rotation
(A) Schematic diagram of the dose-response experiment.
(B) Dose-response relation. Animals injected with 5 mg/kg or 10 mg/kg IVM showed significant AMP-induced rotation when compared to the pretest.
**p < 0.01, two-tailed, paired t tests, using Bonferroni correction for multiple comparisons.
(C) Schematic diagram for the ‘‘on-off’’ study.
(D) On-off response time course at 5 mg/kg IVM. Error bars in (B) and (E) represent ±SEM (n = 3–6 animals per time point). See Table 1 for significance
tests and data for 10 mg/kg IVM.obtained with 5 mg/kg IVM (p < 0.005). Analysis of data
from both time-course experiments using ANOVA, with
time and IVM concentration as parameters, showed
a highly significant change of rotation scores with time
(p < 1015) and IVM concentration (p < 0.01). The recovery
rate was not statistically different at the two concentra-
tions of IVM.42 Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc.In theory, recovery could be due to temporal down-
regulation of the CMV promoter caused by silencing.
However, there was no significant difference in the density
of GluClab-expressing neurons at 24 hr after IVM
injection, when silencing is maximal, versus 6 days after
injection, when silencing had decayed (79.5% ± 2.1%
GFP+/NeuN+ neurons after 24 hr versus 82.3% ± 3.4%
Neuron
GluCl/IVM-Dependent Silencing of Striatal NeuronsGFP+/NeuN+ neurons after 6 days; n = 10 sections/time
point, p > 0.5).
Multiple Cycles of Striatal Silencing by IVM
in GluClab-Expressing Mice
The foregoing data implied that the effects of IVM are re-
versible, when different animals are compared at different
time points after injection. We next sought to determine
whether multiple cycles of reversible inhibition could be
obtained within the same animals. To this end, a single
group of GluClab-expressing animals was repeatedly
tested for AMP-induced rotation at multiple time points af-
ter an initial injection of IVM (10 mg/kg), followed by two
additional IVM injections (Figure 5A). A small but significant
rotation response to AMP could be detected at 4 hr after
the first IVM injection (p < 0.05), with a maximal response
being achieved by 24 hr and persisting for at least
3 days (Figure 5B). The IVM effect declined strongly be-
tween 3 and 6 days but did not decline further at 14
days. Upon a second administration of IVM, the rotation
responsewas restored tomaximal levelswhen the animals
were tested with AMP 24 hr post-IVM injection (Figure 5B).
After 14 additional days, the response had again dropped
to levels similar to those before the second IVM injection. A
third 10 mg/kg IVM injection again restored the maximal
AMP induced rotation response when tested 24 hr later
(Figure 5B). These data indicate that multiple cycles of
IVM-induced silencing and recovery can be obtained
within individual GluClab-expressing animals.
A small but statistically significant level of residual AMP-
induced rotation was observed at 14 days post-IVM injec-
tion (Figure 5B). To determine whether this incomplete
extinction was due to IVM/AMP-induced cell death, we
selected three representative mice that showed low but
significant residual turning after 14 days, relative to that
measured in their pretests (Figure 5C, ‘‘14 days’’). The
brains of these mice were collected and sectioned, and
the density of NeuN+ cells quantified by unbiased stereol-
ogy, within 300 mm of the center of infection (as deter-
mined by costaining for GFP; Figure 1B). Themirror-image
of the contour used for counting was employed for quan-
tification on the contralateral, uninfected side. No signifi-
cant difference in the number of NeuN+ cells per unit vol-
ume was found between the infected and the uninfected
sides (Figure 5D, p > 0.25), indicating that the IVM treat-
ment did not cause detectable cell death.
Apomorphine Induces Rotation in the Same
Direction as Amphetamine, in IVM-Injected
GluClab-Expressing Mice
The foregoing data indicated that unilateral expression of
GluClab in the striatum causes a defect in dopaminergic
neurotransmission, as assessed by AMP-induced rota-
tion. In principle, this effect could be exerted by silencing
of postsynaptic striatal neurons, presynaptic dopaminer-
gic afferents (via retrograde transport of the injected virus
to the substantia nigra), or by both. To determine whether
the effect is primarily presynaptic, we tested the responseof GluCl/IVM animals to apomorphine (APO), an agonist
for postsynaptic dopamine D1 and D2 receptors. Unilat-
eral denervation of dopaminergic afferents to the striatum
causes postsynaptic receptor upregulation and therefore
hypersensitivity to dopaminergic receptor agonists (Ober-
lander and Boissier, 1983; Ungerstedt, 1971). Thus sys-
temic administration of APO to such animals causes rota-
tion in the direction contralateral to the lesioned side,
opposite to the direction obtained with AMP. Therefore,
if the effect of IVM-dependent GluCl-mediated silencing
were exerted primarily through a presynaptic mechanism,
APO should induce turning in the direction opposite to that
induced by AMP. If, however, the effect is exerted post-
synaptically (or both pre- and postsynaptically), then APO
should induce rotation in the same direction as AMP, i.e.,
ipsilateral to the AAV2-injected side, similar to animals
with unilateral kainic acidic induced lesions (Schwarcz
et al., 1979).
The results clearly indicated that systemic administra-
tion of APO (5 mg/kg) 24 hr after injection of 10 mg/kg
IVM caused ipsilateral rotation in GluClab-expressing
mice (Figure 5E; 21.5 ± 4.9, n = 5 animals, ANOVA; p <
0.01). The average rotation scores were lower in APO-
injected than in the AMP-injected mice, consistent with
previous reports that APO unlike AMP does not cause
locomotor hyperactivity. Indeed, APO-treated animals
moved more slowly during the 30 min test period
(Figure 5F; p < 0.05, n = 5) and completed fewer 360 ro-
tations. APO-induced rotations were not observed in ani-
mals injected with either AAV2-a or AAV2-b alone (n = 3
animals each) or in GluClab-expressing animals injected
with APO prior to IVM administration (Figure 5E; 24 hr).
After 14 days, APO-induced circling dropped to levels
barely significantly different from the AAV2-a-alone/
AAV2-b-alone control group (Figure 5E, 14 days). When
animals were given a second 10 mg/kg IVM injection
and tested with APO 24 hr later, the ipsilateral rotation
score returned to levels similar to those obtained 24 hr
after the initial IVM injection (Figure 5E, ‘‘24 hr after IVM
react.’’). Thus, the decay kinetics and reversibility seen
with APO-induced rotation were similar to those observed
with AMP. Taken together, these data support the idea
that the GluCl/IVM system exerts its behavioral effect on
dopaminergic transmission, at least in part, by silencing
postsynaptic striatal neurons.
DISCUSSION
Here, we describe a method that allows reversible electri-
cal silencing of genetically targeted CNS neurons in freely
behavingmice, using a ligand that crosses the BBB.When
AAV-mediated expression of GluClab occurs unilaterally
in the striatum, systemic administration of IVM results in
an AMP- or APO-dependent behavioral phenotype. Slice
recording experiments indicate that this behavioral phe-
notype is correlated with IVM-dependent silencing of
striatal neurons. To our knowledge, this is the first demon-
stration of reversible, genetic suppression of neuronalNeuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc. 43
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(A) Schematic illustrating experimental design. Data from the control (single virus-injected) groups are pooled (magenta line).
(B) Multiple cycles of AMP-induced rotation caused by repeated administration of IVM in (AAV2-a + AAV2-b)-injected animals. None of the control
AAV2-a (n = 3) or AAV2-b (n = 3) animals showed rotation at any of the time points.
(C) Behavioral analysis of three representative animals showing a low but significant residual AMP-induced rotation phenotype 14 days after IVM
injection (paired t test, p < 0.05).
(D) Cell counts using unbiased stereology in the same animals as in (C). Animals do not show any significant cell loss on the infected side (unpaired
t test, assuming equal variance, p > 0.1).
(E) Apomorphine-induced rotation test. APO (5mg/kg) was delivered at the times indicated below the x axis, relative to injection of IVM (10mg/kg; blue
arrows). None of the AAV2-a- or AAV-b-injected animals showed rotation at any time point. *(AAV2-a+AAV2-b)-injected animals showed significant
ipsilateral rotation 24 hr after both the first and second IVM injections. ANOVA for rotation scores with time (post-IVM injection) and GluClab subunits
as parameters; p < 0.001. Post hoc unpaired t test (assuming unequal variance) showed significance for the individual time points; p < 0.01).
(F) Comparison of distance moved during AMP-induced rotation test versus APO-induced rotation test. Animals were injected with 10 mg/kg IVM
24 hr before the rotation test. APO-treated animals moved significantly less distance than AMP-treated animals (p < 0.05; two tailed, unpaired
t test assuming unequal variance).
Error bars in (B)–(F) represent ±SEM.44 Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc.
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mals, triggered by systemic injection of a drug. The kinet-
ics are well suited to many behavioral applications: onset
within hours, a maximal effect that persists for several
days, and reversal within two weeks.
In these experiments, silencing of striatal neurons by
GluCl/IVM was inferred from the unilateral rotations pro-
duced in response to AMP. We chose this behavioral as-
say to obtain proof-of-principle data for the GluCl/IVM
system in vivo, because the striatum provides a large tar-
get for stereotaxic injections, and because AMP-induced
rotations are highly sensitive to unilateral striatal lesions
or dopaminergic denervation (Anden et al., 1966;
Schwarcz et al., 1979). AMP was used for the in vivo ex-
periments to elevate firing of the striatal medium spiny
neurons, which normally fire at rather low rates (Berke
et al., 2004). Because the striatal slice preparations do
not contain nigral dopaminergic neurons, injection of de-
polarizing current was employed to elevate firing rates in
medium spiny neurons. (This tactic was not necessary to
observe the effect of IVM on interneurons, which exhibit
a higher level of spontaneous spiking than do MSNs, in
slices.) The in vivo and slice experiments produced com-
plementary results indicating that spiking was effectively
silenced by IVM exposure in neurons from animals that ex-
pressed GluClab in the striatum. In addition, stereological
counting indicated that the behavioral effect of AMP in
GluCl/IVM mice is not due to striatal cell killing. Finally,
the APO data argue that the behavioral phenotype is
not due to retrograde silencing or killing of nigral dopami-
nergic afferents. Taken together, these data support the
idea that the behavioral effects of AMP in GluCl/IVM
mice indeed reflect silencing of striatal neurons.
Kinetics of IVM-Dependent Silencing by GluCl/IVM
The relatively slow (4–6 hr at 10 mg/kg) onset of IVM ef-
fects in vivo likely reflects its pharmacokinetics. Bath ap-
plication of IVM to acute striatal slice cultures from
GluCl/IVM-expressing animals showed repression of neu-
ronal firing within minutes. Therefore, it is likely that faster
onset kinetics, if desired, could be achieved by ICV admin-
istration of IVM. The persistence of IVM effects over sev-
eral days could be advantageous in experiments where
ongoing silencing is required during extended behavioral
tasks. Nevertheless, the prolonged decay of IVM effects
in vivo may prove problematic in some applications.
Such slow recovery kinetics likely reflect the combined in-
fluence of both ligand clearance/metabolism and the slow
dissociation of IVM fromGluClab or slow turnover of GluCl
subunits. Previous observations have indicated that it can
take up to 8 hr for dissociated hippocampal neurons to re-
cover from IVM-dependent silencing (Slimko et al., 2002),
and we did not observe recovery from silencing during the
time that it was possible to record fromneurons in our slice
preparations. Therefore, other systems for neuronal si-
lencing may be preferable where more rapidly reversible
effects are required (Tan et al., 2006).IVM Is Well-Tolerated at the Cellular and Organismal
Levels at Concentrations Required for
GluCl/IVM-Dependent Silencing
IVM is routinely used for treatment of arthropod and nem-
atode parasitic infections in mice and other mammals
(Chabala et al., 1980; Conole et al., 2003; Geary, 2005).
The concentrations of IVM necessary to elicit a rapid-
onset and consistent silencing phenotype (5 mg/kg and
10mg/kg) are higher than those used for antiparasitic treat-
ment (0.2 mg/kg [Burdett et al., 1997]). However, we did
not observe any adverse effects on locomotor behavior
and/or motor learning in wild-type mice at these doses
(Figure S1). Intraperitoneal injection of 20 mg/kg IVM
and above did induce tremors and partial paralysis in
some animals, consistent with IVM overdose (Roder and
Stair, 1998). Such adverse effects may arise because
IVM is a GABAA receptor agonist at high concentrations
(Dawson et al., 2000). Mice deficient for the mdr1a
P-glycoprotein are 100-fold more sensitive to IVM toxicity
(Schinkel et al., 1996); therefore, IVM is likely cleared from
the brain by this transporter. The 5–10 mg/kg IVM
administered i.p. for silencing thus probably results in
a much lower effective CSF concentration. Evidently,
there exists a window of IVM concentrations in the CNS,
allowing one to silence GluClab-expressing neurons with-
out affecting nonexpressing neurons. Nevertheless, it
would be advisable to test for the IVM sensitivity of each
mouse strain before engaging in behavioral experiments
(Davis et al., 1999).
One concern was whether prolonged expression of the
GluClab channel could be toxic to neurons. On the time-
scale of our experiments, even after repeated cycles of
IVM-induced silencing, unbiased stereology revealed no
difference in neuronal cell density between regions of
high GluClab expression on the injected side of the stria-
tum and the corresponding area on the contralateral unin-
jected side. Thus, it is unlikely that expression of GluClab,
or short term IVM induced silencing, has any toxic effects
on striatal neurons.
Levels of GluClab Expression Required for Silencing
In this study, we employed AAV2 virus-mediated trans-
duction of striatal neurons to test IVM-dependent silenc-
ing, using an AMP-induced rotation assay. Interestingly,
we observed a bimodal distribution in the strength of the
phenotype. The group showing a strong rotation pheno-
type had an 3-fold higher infected volume of striatal
tissue, as determined by quantitative anti-GFP immuno-
histochemistry, than the group showing a weak rotation
phenotype. Moreover, the strength of the behavioral phe-
notype also correlatedwith the percentage of neurons that
were strongly inhibited by IVM, when sampled by slice re-
cording. These data suggest that the number of neurons
infected in the striatummust be above a certain threshold,
in order to elicit a strong rotation phenotype. However,
other studies have found a more gradual correlation be-
tween the size of striatal lesions and the AMP-induced ro-
tation phenotype (Kirik et al., 1998; Olds et al., 2006). TheNeuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc. 45
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fact that both the levels of GluClab expression, as well as
the number of infected neurons, are likely to be lower in
subthreshold animals (Figure 3), whereas in lesion exper-
iments only the number of killed cells is variable.
In animals showing a strong rotational phenotype,
80% of the neurons within the infected area expressed
GluClab (assessed using anti-GFP antibody), and 50%
of the cells showed a high level of expression of both sub-
units (assessed usingCFP/YFP native fluorescence). Con-
sistent with this, 70% of the neurons in slices from such
animals exhibited reduced spiking in response to bath-ap-
plied IVM, and70% of such neurons were fully inhibited.
Furthermore, we observed a strong correlation between
GluClab channel subunit expression levels and inhibition
of firing by IVM, in individual neurons retrospectively iden-
tified by dye filling. Complete inhibition of spiking was ob-
served in cells expressing GluClab at levels more than 15-
fold lower than the highest levels detectable in the slices.
Thus, while very high levels of GluClab expression can be
achieved using the AAV2 expression system, efficient si-
lencing of striatal neurons does not require maximal levels
of expression.
The question arises as to whether cellular promoters,
rather than the strong viral promoter (CMV) used in our ex-
periments, would drive sufficient levels of GluCl subunit
expression to achieve silencing. In ongoing experiments,
we have obtained behavioral phenotypes in mice in which
the GluCla subunit was expressed from a cellular
promoter, using a BAC transgene, and the b subunit was
provided by AAV2 injection (W. Haubensak andD.J.A., un-
published data). However, other experiments, using a dif-
ferent cellular promoter to express both subunits, have
been less successful. In practice, the level of GluCl ex-
pression necessary to silence a given type of neuron will
depend on the intrinsic strength of the chosen promoter,
the number of copies and chromosomal integration site
of the transgene, and the surface membrane area of the
targeted neuron subtype. The uncertainties associated
with this type of approach could be reduced by condition-
ally expressing GluCl from a strong constitutive promoter
(such as CMV) and using cell-specific promoters to ex-
press Cre or FLP recombinase, thereby enabling GluCl
expression in a specific pattern at high levels.
Extent of Reversibility of Silencing by GluCl/IVM
The GluCl/IVM silencing method is, in principle, not only
inducible, but also reversible. In time-course experiments
on animals each receiving a single injection of IVM and
tested with AMP at a single time point, we observed a re-
turn to very low, nonsignificant levels of rotation by 4 to 5
days after the initial IVM injection (Figure 4D). These data
suggest that GluCl/IVM-dependent silencing is fully re-
versible. However, in animals receiving multiple tests with
AMP over several days, residual turning was observed
even at 14 days after IVM injection (Figures 5B and 5C).
It is unlikely that this small amount of residual turning
is due to prolonged silencing of a portion of neurons46 Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc.because animals receiving a single AMP injection 14 days
after IVM administration showed almost no detectable
rotation (Figure 4D). The reason for this difference is cur-
rently unclear but could involve cumulative effects of mul-
tiple AMP injections or behavioral conditioning caused by
directional bias during the repeated AMP-induced rotation
tests. The reversibility of the system was confirmed by the
fact that a second injection of IVM, two weeks after the
first one, restored the phenotype to the levels observed af-
ter the initial injection, when tested with AMP 24 hr later.
A Combinatorial Strategy for Increased Specificity
of Genetic Neuronal Silencing
Genetically based neuronal silencing will be useful for the
behavioral analysis of neuronal circuits defined by molec-
ular markers. The requirement for two subunits to encode
a functional GluClab receptor is an advantageous feature
of this system. Global analyses of gene expression in the
CNS (Gong et al., 2003; Heintz, 2004; Lein et al., 2007)
have indicated that, while there are many genes that de-
fine neuronal subsets in specific areas of the brain, most
such genes are expressed in several other brain areas
and/or in other regions of the body. Probably, very few
promoters are exclusively expressed in a single neuronal
subtype within a single brain region (Gong et al., 2003;
Heintz, 2004; Zhang et al., 2001). The need for two GluCl
subunits permits, in principle, a refinement of cell-type
or regional silencing in the brain by using two different pro-
moters, with partially overlapping specificities, to drive
expression of each subunit. Such an approach has the
advantage that all mice will express the two subunits in
a reproducible pattern, minimizing animal-to-animal
variability in the extent of silencing. However, it requires
identification of promoter combinations with the requisite
limited overlap.
A combinatorial approach can also be achieved by ste-
reotaxic injection of a virus encoding one GluCl subunit
into the brain region of interest in a transgenic mouse in
which the other subunit is expressed under the control
of a specific promoter. In this way, only neurons express-
ing the specific promoter within the injected region will be
silenced. Although this method suffers frommore inherent
variability, due to the imprecision of injections, it has the
advantage that a single mouse line can be exploited to
silence neurons in whichever brain regions express the
complementary GluCl subunit transgene. Expression of
the two GluCl subunits using two viruses containing cell-
specific promoters, rather than the constitutive CMV pro-
moter used here, is also possible. This strategy can also
be applied to experimental organisms in which routine
transgenesis is difficult, such as nonhuman primates.
While combinatorial approaches are not unique to the
GluCl system (Gosgnach et al., 2006; Karpova et al.,
2005; Tan et al., 2006), their application will likely become
increasingly necessary as more specific manipulations of
neuronal subsets are required.
The GluCl/IVM method is a promising new tool for
studying the behavioral effects of inducibly and transiently
Neuron 54, 35–49, April 5, 2007 ª2007 Elsevier Inc. 47
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brain. It adds to the growing repertoire of techniques for
genetically encoded inhibitors of neuronal activity or neu-
rotransmission (reviewed in Callaway [2005]). While each
of these methods has particular shortcomings, their appli-
cation in combination should permit rigorous tests of
causal relationships among the firing of individual cell
types, activity of neuronal circuits, and behavior.
EXPERIMENTAL PROCEDURES
Constructs and Virus Production
The woodchuck hepatitis posttranscriptional regulatory element
(WPRE) was inserted between the ClaI and the XhoI restriction site
of the Multiple Cloning sequence (MCS) of the pAAV-MCS vector of
the AAV Helper-Free System (Stratagene 240071). The synthetically
generated sequences for optGluCla-CFP or optGluClbY182F-YFP
(Slimko and Lester, 2003) were then cloned into the ClaI site to pro-
duce pAAV-GluCla and pAAV-GluClb, respectively. Both constructs
were commercially packaged and serotyped with the AAV2 capsid
protein by Virapure, Inc., using the AAV Helper-Free System (Strata-
gene 240071).
Animal Maintenance
C57B6 male mice bred at the California Institute of Technology
(founders originally purchased from Charles River) were housed with
ad libitum access to food and water. The temperature was maintained
at 23C and lights were set to 13 hr day, 11 hr night cycle (day cycle
starting at 10 p.m.). Mice were singly housed at least 24 hr prior to sur-
gery. Singly housed mice were given a red plastic house for environ-
mental enrichment.
Stereotaxic Surgery
Stereotaxic injections were performed using standard procedures.
Details are available in Supplemental Experimental Procedures.
Ivermectin and Vehicle Intraperitoneal Injections
A 1% sterile solution of Ivermectin (Phoenectin, AmTech) was diluted
with sterile propylene glycol to the appropriate dilution and injected
i.p. at 1ml/g animal body weight. Vehicle-injected animals received
injections of 1ml/g animal body weight of propylene glycol without IVM.
AMP and APO-Induced Rotation Test
AMP, d-Amphetamine sulfate (Sigma A-5880), or APO, R-()-Apomor-
phine hydrochloride hemihydrate (Sigma A4393-1G) were dissolved in
sterile PBS at 10 mg/ml and diluted to 1 mg/ml in sterile saline for i.p.
injections. Mice received i.p. injections of 5 mg/kg of either AMP or
APO in their home cage and were placed into a box in the openfield
setup within 2–5 min. The open field setup was made of four open
acrylic boxes, each 553 55 cmwide, with 15 cm high walls. Themove-
ment of up to four mice was recorded with a top-mounted camera and
captured with the Mediacruise program (Canopus). The movie files
were then analyzed using the Ethovision software (Noldus). Traces
for each mouse were recorded for 30 min, starting 10 min after the
mouse had been placed into the open field setup. Rotation scores (ip-
silateral circles per 10 min) were calculated by subtracting contralat-
eral rotations from ipsilateral rotations and dividing the result by the
total distance moved.
Histology
optGluCla-CFP, optGluClbY182F-YFP, and NeuN antigen were visual-
ized on 120 mm vibratome section slices or 30 mm frozen sections by
antibody staining against GFP (Molecular Probes A11122) and NeuN
(Chemicon MAB377). See Supplemental Experimental Procedures
for a detailed description of the procedure. For visualization of nativeYFP or CFP, a mock-staining procedure (no addition of antibody)
was performed in order to reduce autofluorescence.
Cell Quantification
GFP staining was performed on 120 mm floating sections. Using the
Stereo Investigator software (Microbrightfield, Inc) the area of the
most intense staining was contoured, approximately circumscribing
a radius of 300 mm from the injection site in the right striatum. The con-
tour was saved, and a mirror image of the contour was created on the
left side of the striatum (control side). A random raster was created by
the software and cells were counted in three dimensions, excluding the
top and bottom 10 mmof each section. Movement along the raster was
controlled by the software using a motorized stage. The counts were
extrapolated for each sample (three sections per mouse) and had an
estimated coefficient of error (Scheaffer) <0.05.
Volume Estimation
The area of red anti-GFP staining was contoured on each section using
the Stereo Investigator software. The surface area of the contour was
automatically calculated, multiplied by the 120 mm section thickness,
and added up over all sections that showed staining for the GFP
antigen.
Slice Preparation for Electrophysiology
Striatal slices were prepared as described (Ye et al., 2006), with minor
modifications. See Supplemental Experimental Procedures for details.
Electrophysiological Recordings
A single slice was transferred into the 0.8 ml recording chamber.
Throughout the experiments, the bath was continually perfused with
ACSF (1.5–2.0 ml/min). Cells were visualized with an upright micro-
scope (BX 50WI, Olympus) and near-infrared illumination. The patch
electrodes had a resistance of 5–8 MU, when filled with pipette solu-
tion: 135 mM Potassium gluconate, 5 mM EGTA, 0.5 mM CaCl2,
2 mM MgCl2, 10 mM HEPES, 2 mM Mg-ATP, and 0.1 mM GTP. The
pH of the pipette solution was adjusted to 7.2 with tris-base and the
osmolarity to 280–300 mOsm with sucrose. The action potential firing
was recorded, in the mode of whole-cell current clamp or loose-patch
cell-attached voltage clamp, with MultiClamp 700B amplifiers (Axon
Instruments), a Digidata 1200A A/D converter, and pCLAMP 9.2 soft-
ware (Axon Instruments). Data were sampled at 10 kHz and filtered
at 2 kHz. The junction potential between the patch pipette and the
bath solution was nulled just before gigaseal formation. Recordings
were performed at 32C.
Quantification of CFP and YFP Fluorescence following
Electrophysiology
For retrospective quantification of CFP and YFP fluorescence, Alexa
Fluor 647 dextran (Invitrogen Inc., catalog number, D-22914) was dis-
solved in intrapipette solution (0.02%), backfilled in the recording elec-
trode, and injected into the recorded neuron during whole-cell patch
clamp recording. See Supplemental Experimental Procedures for
details on fluorescence quantification.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/54/1/35/DC1/.
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